scholarly journals Differential Expression of Androgen Receptor in Type I and Type II Endometrial Carcinomas: A Clinicopathological Analysis and Correlation with Outcome

2021 ◽  
Vol 36 (2) ◽  
pp. e245-e245
Author(s):  
Nisreen Abu Shahin1 *, ◽  
Tariq Aladily ◽  
Nezeen Abu Alhaj ◽  
Ali Al-Khader ◽  
Shefa’ Alqaqa ◽  
...  
Keyword(s):  
Androgen Receptor ◽  
Tumor Stage ◽  
Clinicopathological Parameters ◽  
Lower Grade ◽  
Type I ◽  
Type Ii ◽  
Node Status ◽  
Clinicopathological Analysis ◽  
Alive With Disease ◽  
Endometrial Carcinomas

Objectives: Endometrial carcinomas (EC) are the most common gynecological malignancies and are conventionally divided into type I and type II due to diagnostic and prognostic considerations. Female hormone expression in EC is extensively studied; however, data about androgen receptor (AR) expression in EC are sparse. We aimed to study AR expression in different types of EC at our institute and whether it had an impact on patient outcomes. Methods: A retrospective analysis of EC cases diagnosed and treated from 2010–2019. AR immunohistochemical expression was tested in 52 EC cases (type I = 40; type II = 12). Histological typing was verified according to conventional diagnostic criteria. Only primary EC were included without neoadjuvant therapy. Histologic score was calculated as: stain intensity (graded 0–3) × positive cells percentage (graded 0–4). Level of expression was scored from 0 to 12. Results: The mean age of the selected patients was 60.3 years (range = 31–88 ± 12.6). Recurrence was detected in 11 (21.2%) patients. The outcome was 40 patients were alive without disease, eight alive with disease, three dead of disease, and one dead of other causes. About 62.5% of type I-EC and 25.0% of type II-EC were AR positive. AR expression was analyzed against different clinicopathological parameters including: type (p = 0.005), histotype (p = 0.044); grade (p = 0.035); age group (p = 0.207); menopause (p = 0.086); estrogen receptor (ER) expression (p = 0.284); atypical complex hyperplasia (p = 0.594); tumor stage (p = 0.994); tumor recurrence (p = 0.530); node status (p = 0.110); and outcome (p = 0.202). Conclusiosn: AR expression was higher in type I EC, endometrial endometrioid carcinoma histotype, and with a lower grade. AR expression was not significantly correlated with age, stage, ER, atypical hyperplasia, recurrence, node status, or outcome. Results agree with recent literature that AR expression is associated with better-differentiated EC and may be a potential hormonal therapeutic tool.

scholarly journals Type II endometrial cancers: original research on a series

2017 ◽  
Vol 6 (6) ◽  
pp. 2306
Author(s):  
B. L. Nayak ◽  
Sujata Misra ◽  
Suryakant Jaysingh ◽  
S. K. Giri
Keyword(s):  
Clear Cell ◽  
Myometrial Invasion ◽  
Serous Carcinoma ◽  
Original Research ◽  
Clear Cell Adenocarcinoma ◽  
Type I ◽  
Type Ii ◽  
Clinicopathological Analysis ◽  
Hematoxylin And Eosin ◽  
Endometrial Carcinomas

Background: Endometrial carcinoma, which ranks 3rd in India amongst the gynecological malignancies, is of two histological types: I and II. These differ in molecular as well as in clinical and histopathological profiles. Type II is estrogen independent, nonendometrioid, with higher grade histologies, more aggressive and carries an adverse prognosis.Methods: Endometrial carcinomas diagnosed from endometrial biopsies and hysterectomy specimens in the Dept of Gynaec-oncology, AHRCC, Cuttack from November 2009 to January 2015 were included in the study. All specimens were fixed in 10% neutral buffered formalin and paraffin embedded for histological examination with hematoxylin and eosin staining. The clinicopathological analysis of the cases of EC was done with an emphasis on morphology.Results: Of a total of 150 cases of EC reported, 20 cases were classified as type II EC (13.33%) as per histology. The age of the patients ranged from 36 to 73 years, with mean age is 61 years. In 11 cases (55%), the myometrial invasion was more than half. the histological type was a clear cell adenocarcinoma in 50% of the cases. All were treated with hysterectomy and chemotherapy.Conclusions: Of the type II EC, serous carcinoma is the most common type. Clinical presentation and prognosis differs in comparison to type I EC, thus the recognition of this type of EC is pivotal.

Gastric carcinoids: Does type of surgery or tumor affect survival?

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 139-139
Author(s):  
Angelena Crown ◽  
Zaheer S. Kanji ◽  
Alexandra G Lopez-Aguiar ◽  
Mary Dillhoff ◽  
George A. Poultsides ◽  
...  
Keyword(s):  
Clinicopathological Parameters ◽  
Gastric Carcinoid ◽  
Type I ◽  
Tumor Type ◽  
Type Ii ◽  
Long Term Outcomes ◽  
Type Iii ◽  
Gastric Carcinoids ◽  
Type Iv

139 Background: Gastric carcinoids are rare neuroendocrine tumors of the GI tract. They are typically managed according to their etiology. However, there is little known about the impact of surgical strategy on the long-term outcomes of these patients. Methods: All patients who underwent resection of gastric carcinoids at 8 institutions from 2000-2016 were analyzed retrospectively. Tumors were stratified according to subtype (I, II, III, IV) and resection type (local resection LR or formal gastrectomy FG). Clinicopathological parameters, recurrence-free (RFS), and overall survival (OS) were compared between groups. Results: Of 79 patients identified with gastric carcinoids, 34 had type I lesions associated with atrophic gastritis, 4 had type II lesions associated with a gastrinoma, 37 had type III sporadic lesions, and 4 had type IV poorly-differentiated lesions. The mean age of presentation was 56 years in predominantly Caucasian (77%) and female (63%) patients. Mean tumor size was 2.4 cm and multifocal tumors were found in 24 (30%) of patients with the majority occurring in those with type I tumors. Lymph node positive tumors were seen in 15 (19%) patients and 7 (8%) had M1 disease; both most often in type IV followed by type III tumors. R0 resection was achieved in 56 (71%) patients while 15 (19%) had R1 resections and 6 (8%) had R2 resections. Patients with type I and III tumors were equally likely to have a LR (50% and 43% respectively) compared to FG while those with type II and IV all had FG with one exception. Type IV tumors had the poorest RFS and OS while Type II tumors had the most favorable RFS and OS (p < 0.04 and p < 0.0004, respectively). While there was no difference in RFS in those patients undergoing FG versus LR, OS was worse in the FG group (p < 0.017). This trend persisted when type II and type IV groups were excluded (p < 0.045). Conclusions: Gastric carcinoid treatment should be tailored to tumor type, as biologic behavior rather than resection technique is the more important factor contributing to long-term outcomes.

scholarly journals Molecular Profiling of Endometrial Malignancies

2010 ◽  
Vol 2010 ◽  
pp. 1-16 ◽  
Author(s):  
Norasate Samarnthai ◽  
Kevin Hall ◽  
I-Tien Yeh
Keyword(s):  
Fusion Gene ◽  
Endometrial Stromal Sarcoma ◽  
Molecular Profiling ◽  
Genetic Alterations ◽  
Endometrial Neoplasms ◽  
Low Grade ◽  
Type I ◽  
Type Ii ◽  
Molecular Changes ◽  
Endometrial Carcinomas

Molecular profiling of endometrial neoplasms reveals genetic changes in endometrial carcinomas that support the dualistic model, in which type I carcinomas are estrogen-dependent, low grade lesions and type II carcinomas are nonestrogen dependent and high grade. The molecular changes in type I endometrial carcinomas include mutations inPTEN, PIK3CA, KRAS,and -catenin, along with microsatellite instability, whereas type II endometrial carcinomas are characterized by genetic alterations inp53, HER2/neu, p16,and E-cadherin. For endometrial neoplasms with a malignant mesenchymal component,C-MYCmutations and loss of heterozygosity are frequently seen in carcinosarcomas, and a fusion gene,JAZF1/JJAZ1, is distinctive for endometrial stromal sarcoma. In addition,p53mutations may play an important role in tumorigenesis of undifferentiated endometrial sarcoma. These molecular changes can help in the diagnosis of endometrial neoplasms, as well as form the basis of molecular targeted therapy.

scholarly journals Increased expression of hypoxia-inducible factor 1α in type I and type II endometrial carcinomas

2006 ◽  
Vol 20 (1) ◽  
pp. 35-43 ◽  
Author(s):  
Vaishali Pansare ◽  
Adnan R Munkarah ◽  
Veronica Schimp ◽  
M Haitham Arabi ◽  
Ghassan M Saed ◽  
...  
Keyword(s):  
Hypoxia Inducible Factor ◽  
Type I ◽  
Type Ii ◽  
Hypoxia Inducible Factor 1Α ◽  
Endometrial Carcinomas

scholarly journals Combined genetic mutations and DNA-methylated genes as biomarkers for endometrial cancer detection from cervical scrapings

2019 ◽  
Vol 11 (1) ◽  
Author(s):  
Phui-Ly Liew ◽  
Rui-Lan Huang ◽  
Tzu-I Wu ◽  
Chi-Chun Liao ◽  
Chien-Wen Chen ◽  
...  
Keyword(s):  
Dna Methylation ◽  
Endometrial Cancer ◽  
Cancer Detection ◽  
Type I ◽  
Type Ii ◽  
Normal Endometrium ◽  
Epigenetic Biomarkers ◽  
Pap Smear Screening ◽  
Endometrial Cancers ◽  
Endometrial Carcinomas

Abstract Background Endometrial cancer is a common gynecologic cancer. Noninvasive molecular biomarkers for triage of high-risk patients for invasive procedures are needed. Based on the success of cytological Pap smear screening, cervical scrapings are a good source of DNA for molecular testing. In addition to genetic lesions, DNA methylation is a promising biomarker. We assessed the usefulness of combining genetic and epigenetic biomarkers from cervical scrapings to detect endometrial carcinomas. Methods We performed a retrospective case–control study of 96 consecutive cervical scrapings from patients with abnormal uterine bleeding who underwent surgery for diagnostic evaluation. Thirty and 16 cases were diagnosed with type I and type II endometrial cancers, respectively. The remaining non-cancer cases included normal endometrium (n = 12), benign uterine lesions (n = 20), and endometrial hyperplasia (n = 18). Quantitative methylation-specific PCR and mass spectrometry were used for DNA methylation and genetic mutation analysis. Logistic regression was used to evaluate the clinical performance of these candidate biomarkers. Results We tested the effectiveness of the methylation status of four genes (BHLHE22, CDO1, TBX5, and HAND2) in endometrial cancer detection. The area under the receiver operating characteristic curves ranged from 0.703 to 0.878, and panels of hypermethylated BHLHE22/CDO1/HAND2 (87.0% sensitivity and 86.0% specificity) and BHLHE22/CDO1/TBX5 (89.1% sensitivity and 80.0% specificity) showed significant differences and could distinguish benign from malignant endometrial lesions. The sensitivity and specificity in endometrial cancer detection for BHLHE22/CDO1 were 84.8% and 88.0%, respectively. Both type I and II endometrial carcinomas could be detected using a BHLHE22/CDO1-based methylation profile, suggesting that they may have common epigenomes. Moreover, PTEN and TP53 mutations were found in 63.3% of type I and 93.6% of type II endometrial cancers. Unexpectedly, PTEN and TP53 mutations were commonly found in cervical scrapings of the normal endometrium (25% and 33.3%, respectively) and in cases with benign uterine lesions (10% and 50%, respectively). Finally, combinations of any one mutation of PTEN and TP53 mutations had a sensitivity of 91.3%, but a specificity of only 42.0%. Conclusions Adding PTEN/TP53 mutation testing to BHLHE22/CDO1-based methylation testing did not improve the detection of endometrial cancer.

scholarly journals Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: A search for biomarkers of sensitivity to treatment

2010 ◽  
Vol 119 (3) ◽  
pp. 579-585 ◽  
Author(s):  
Victoria L. Bae-Jump ◽  
Chunxiao Zhou ◽  
John F. Boggess ◽  
Young E. Whang ◽  
Lisa Barroilhet ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Type I ◽  
Type Ii ◽  
Endometrial Carcinomas
Sign in / Sign up

Export Citation Format

Share Document